Life Science REIT (LABS) Share Price, News & Analysis

Company Overview

Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange. The registered office of the Company is located at 6th Floor, 65 Gresham Street, London, EC2V 7NQ.

Key Stats

• Today's Range: 43.80 to 44.12
• 50-Day Range: 41.20 to 48.60
• 52-Week Range: 31.30 to 49
• Volume: 180,215 shs
• Average Volume: 786,669 shs
• Market Capitalization: £156.21 million
• P/E Ratio: N/A
• Dividend Yield: 4.55%
• Price Target: GBX 46.50
• Consensus Rating: Moderate Buy

LABS Stock Analysis - Frequently Asked Questions

How have LABS shares performed this year?

Life Science REIT's stock was trading at GBX 38 at the start of the year. Since then, LABS shares have increased by 15.8% and is now trading at GBX 44.

How were Life Science REIT's earnings last quarter?

Life Science REIT plc (LON:LABS) posted its quarterly earnings results on Wednesday, April, 16th. The company reported $1.70 EPS for the quarter. Life Science REIT had a negative net margin of 198.99% and a negative trailing twelve-month return on equity of 14.53%.

How do I buy shares of Life Science REIT?

Shares of LABS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Company Calendar

• Last Earnings: 4/16/2025
• Today: 7/04/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Real Estate
• Industry: REIT - Healthcare Facilities
• Sub-Industry: N/A
• Current Symbol: LON:LABS
• CIK: N/A
• Web: www.lifesciencereit.co.uk
• Phone: 44-20-7945-9566
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 46.50
• High Stock Price Target: GBX 57
• Low Stock Price Target: GBX 36
• Potential Upside/Downside: +5.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (11.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£40.62 million
• Net Margins: -198.99%
• Pretax Margin: N/A
• Return on Equity: -14.53%
• Return on Assets: 1.25%

Debt

• Debt-to-Equity Ratio: 44.18
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: £20.41 million
• Price / Sales: 7.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 76.35 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 355,028,736
• Free Float: N/A
• Market Cap: £156.92 million
• Optionable: Not Optionable
• Beta: 0.08